GILEAD SCIENCES SL
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 376
- Registration Number
- NCT05007782
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Smilow Cancer Center, New Haven, Connecticut, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
- Conditions
- Solid Malignancies
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 145
- Registration Number
- NCT05006794
- Locations
- 🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Drug: Placebo SC LENDrug: PTM F/TDFDrug: PTM F/TAFDrug: PTM Oral LEN
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 5368
- Registration Number
- NCT04994509
- Locations
- 🇿🇦
Emavundleni Research Centre, Cape Town, South Africa
🇿🇦The Aurum Institute: Rustenburg Clinical Research Centre, Rustenburg, South Africa
🇿🇦Synergy Biomed Research Institute (SBRI), East London, South Africa
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 457
- Registration Number
- NCT04971785
- Locations
- 🇺🇸
Charter Research, Winter Park, Florida, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Rush University Medical Group - Department of Hepatology, Chicago, Illinois, United States
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 92
- Registration Number
- NCT04958785
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇺🇸Charleston Oncology, Charleston, South Carolina, United States
🇦🇺Peninsula Health, Frankston, Victoria, Australia
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
- Conditions
- Hepatic ImpairmentPrimary Biliary CholangitisCompensated Cirrhosis
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT04950764
- Locations
- 🇺🇸
Southern Therapy and Advanced Research LLC, Jackson, Mississippi, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
- Conditions
- Pre-Exposure Prophylaxis of HIV Infection
- Interventions
- Drug: Placebo SC LENDrug: F/TAF (for US participants only)Drug: PTM F/TDFDrug: PTM Oral LEN
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 3295
- Registration Number
- NCT04925752
- Locations
- 🇺🇸
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Los Angeles, California, United States
🇺🇸Howard Brown Health Center, Chicago, Illinois, United States
🇺🇸The Crofoot Research Center, INC, Houston, Texas, United States
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 103
- Registration Number
- NCT04891770
- Locations
- 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇩🇰Odense University Hospital, Odense, Denmark
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 193
- Registration Number
- NCT04854499
- Locations
- 🇺🇸
UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Memorial Healthcare System, Hollywood, Florida, United States
🇧🇪Algemeen Ziekenhuis Klina, Brasschaat, Belgium